Skip to main content
Atrás
Watch Compare

Decoy Therapeutics Inc.

Calidad de datos: 83%
DCOY
Nasdaq Manufacturing Chemicals
$6.00
▲ $0.37 (6.57%)
Cap. Mercado: 3.19 M
Precio
$6.00
Cap. Mercado
3.19 M
Rango del Día
$5.63 — $6.05
Rango de 52 Semanas
$5.40 — $415.80
Volumen
13,340
Apertura $5.80
Promedio 50D / 200D
$8.14
26.27% below
Promedio 50D / 200D
$48.08
87.52% below

Quick Summary

Puntos Clave

Negative free cash flow of -4.83 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-732.43%
Below sector avg (-53.47%)
ROIC-266.10%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valoración

PE (TTM)
-0.25
Above sector avg (-1.47)
P/B Ratio0.75
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -0.3 -1.5
P/B 0.8 1.6
ROE % -732.4 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12.52 M
ROE -732.43% ROA -334.28%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -4.83 M
ROIC -266.10% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 4.25 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.25 Forward P/E N/A
P/B Ratio 0.75 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -151.22%
Market Cap 3.19 M Enterprise Value -1.62 M
Per Share
EPS (Diluted TTM) -129.10 Revenue / Share N/A
FCF / Share -9.07 OCF / Share -9.07
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 38.56%
SBC-Adj. FCF -4.97 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 0.0 1.84 M
Net Income -12.52 M -5.58 M -12.54 M -31.61 M -12.77 M
EPS (Diluted) -129.10 -5.79 -3.84 -14.88 -0.31
Gross Profit — — — — —
Operating Income -12.61 M -5.73 M -12.89 M -31.84 M -12.81 M
EBITDA — — — — —
R&D Expenses 368,170.0 770,027.0 7.17 M 15.84 M 8.55 M
SG&A Expenses — — — — —
D&A 7,151.0 4,424.0 10,051.0 6,677.0 19,183.0
Interest Expense — — — — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11.06 M 3.02 M 6.59 M 14.65 M 40.83 M
Total Liabilities 5.17 M 1.51 M 1.30 M 4.27 M 2.11 M
Shareholders' Equity 5.89 M 1.51 M 5.29 M 10.38 M 38.72 M
Total Debt — — — — —
Cash & Equivalents 10.71 M 2.43 M 5.90 M 12.11 M 29.21 M
Current Assets 10.99 M 2.99 M 6.52 M 14.52 M 30.16 M
Current Liabilities 5.17 M — — — —